Published in Cancer Weekly, December 17th, 2002
Researchers who work for INSERM in Toulouse, France, used somatostatin receptor subtype 2 (sst2) gene therapy to subdue both primary and metastatic human pancreatic cancer lesions growing in immunocompromised mice. Sst2 has antioncogenic properties with a reach that extends beyond tumors treated locally, according to a new report.
Fabienne Vernejoul and colleagues said the sst2 genes, when delivered to cancer cells via adenovirus or a synthetic polycationic carrier (PEI), generated transgene expression at...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.